Thymidylate Synthase: A Critical Target for Cancer Chemotherapy
- 1 February 2002
- journal article
- review article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 1 (4) , 220-229
- https://doi.org/10.3816/ccc.2002.n.003
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesotheliomaEuropean Journal Of Cancer, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysisThe Lancet, 2000
- Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinomaCancer, 2000
- Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeksEuropean Journal Of Cancer, 1999
- Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeksEuropean Journal Of Cancer, 1999
- The role of thymidylate synthase as an RNA binding proteinBioEssays, 1996
- Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase.Cell Structure and Function, 1995
- Preclinical and clinical aspects of biomodulation of 5-fluorouracilCancer Treatment Reviews, 1994
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957